Investor relations (EN)
Read more:
Welcome to Nanologica’s investor relations section.
Nanologica develops, manufactures, and sells nanoporous silica particles for applications within life science. We are world-leading in controlling the shape, size, porosity, and surface properties of silica particles, which creates opportunities to develop unique products within our two business areas Chromatography and Drug Development.
In Chromatography, we aim to make insulin and other peptide drugs available to more patients by providing products that can lower the production costs of these drugs at the manufacturers.
In Drug Development, we develop a unique drug delivery platform for local delivery of drugs to the lung , to provide new treatment options for patients with lung diseases.
On this investor relation site, you can find news, financial reports, share info, upcoming events and more.
Our ambition is to update shareholders as well as the capital market on our status and progress regularly. This is done via press releases, financial reports, video comments and presentations at various life science, biotech and investment events. Due to our large presence in the Swedish market, some material in this section is only available in Swedish. If you have any questions, kindly contact us at ir@nanologica.com.
To subscribe to our press releases and financial reports, please enter your e-mail address in the box below. You will then receive an e-mail where you need to confirm your subscription.
For further information, please contact:
Johanna Johansson
Director IR, Communications and Marketing
